In a phase 1b/2 study, combining cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, with chemotherapy showed promising efficacy in gastroesophageal junction adenocarcinoma, with an objective response rate of 52.1% [166]. The gene discussed is PDCD1; the disease is gastroesophageal junction adenocarcinoma.